MeiraGTx (MGTX)
6.80
0.10 (1.49%)
At close: Apr 28, 2025, 9:34 AM
1.49% (1D)
| Bid | 4.86 |
| Market Cap | 536.43M |
| Revenue (ttm) | 33.28M |
| Net Income (ttm) | -147.79M |
| EPS (ttm) | -2.12 |
| PE Ratio (ttm) | -3.21 |
| Forward PE | -50.46 |
| Analyst | Buy |
| Ask | 8.8 |
| Volume | 4,775 |
| Avg. Volume (20D) | 579,732 |
| Open | 6.71 |
| Previous Close | 6.70 |
| Day's Range | 6.71 - 6.83 |
| 52-Week Range | 3.85 - 8.75 |
| Beta | 1.22 |
About MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical develop...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 8, 2018
Employees 375
Stock Exchange NASDAQ
Ticker Symbol MGTX
Website https://www.meiragtx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MGTX stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 260.15% from the latest price.
Stock Forecasts1 month ago
+28.71%
MeiraGTx shares are trading higher. The company re...
Unlock content with
Pro Subscription
2 months ago
+6.88%
MeiraGTx shares are trading higher after the company announced the publication of results from its first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy.
